Brief: Sino Biopharmaceutical Says Application For Marketing Of TQG203 Accepted By China's NMPA
13/12/2023 10:31
Dec 13 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* APPLICATION FOR MARKETING OF TQG203 "RECOMBINANT HUMAN
COAGULATION FACTOR VIIA FOR INJECTION" FILED AND ACCEPTED
* DRUG FILED WITH AND ACCEPTED BY NATIONAL MEDICAL PRODUCTS
ADMINISTRATION OF CHINA
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up